Nature`s Sunshine Products Overview
Nature`s Sunshine Products (NATR) has a ROE of 11.92%, below the Healthcare sector average of 29.33%.
Get informed when a big investor buys or sells
+ Follow11.92%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Nature`s Sunshine Products posts a ROE of 11.92%. That is below the Healthcare sector average of 29.33%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
For Healthcare stocks, a ROE near 29.33% is typical. Nature`s Sunshine Products's 11.92% is lower that level. That is roughly 59.4% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.
Nature`s Sunshine Products's ROE moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is 11.92%; use YoY and peer views to separate noise from signal.
Context for NATR's ROE usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 29.33%), and (3) consistency with growth and profitability. This page covers the first two; Nature`s Sunshine Products's other metric pages and overview cover the third.
Judging Nature`s Sunshine Products against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in ROE easier to interpret. Start with 11.92% here, then scan peer and history charts to see if the gap is persistent.
